Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
O Mir, L Mouthon, J Alexandre… - Journal of the …, 2007 - academic.oup.com
Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) is a recombinant
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …
[PDF][PDF] Bevacizumab-Induced Cardiovascular Events: A Consequence of Cholesterol Emboli Syndrome?
2007 - researchgate.net
Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) is a recombinant
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …
[引用][C] Bevacizumab-Induced Cardiovascular Events: A Consequence of Cholesterol Emboli Syndrome?
O Mir, L Mouthon, J Alexandre, JM Mallion… - Journal of the National …, 2007 - elibrary.ru
[引用][C] Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
O Mir, L Mouthon, J Alexandre… - Journal of the …, 2007 - pubmed.ncbi.nlm.nih.gov
Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome …
Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome …
[HTML][HTML] Bevacizumab-Induced Cardiovascular Events: A Consequence of Cholesterol Emboli Syndrome?
Journal of the National Cancer Institute: JNCI., 2007 - books.google.com
Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) is a recombinant
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …
[引用][C] Bevacizumab-Induced Cardiovascular Events: A Consequence of Cholesterol Emboli Syndrome?
O Mir, L Mouthon, J Alexandre, JM Mallion… - JNCI: Journal of the …, 2007 - cir.nii.ac.jp
[引用][C] Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
O Mir, L Mouthon, J Alexandre, JM Mallion… - Journal of the …, 2007 - europepmc.org
Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
- Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
- Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
[PDF][PDF] Bevacizumab-Induced Cardiovascular Events: A Consequence of Cholesterol Emboli Syndrome?
2007 - Citeseer
Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) is a recombinant
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …
[引用][C] Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
O MIR - J Natl Cancer Inst, 2007 - cir.nii.ac.jp
Bevacizumab-induced cardiovascular events : a consequence of cholesterol emboli syndrome?
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
[HTML][HTML] Bevacizumab-Induced Cardiovascular Events: A Consequence of Cholesterol Emboli Syndrome?
Journal of the National Cancer Institute: JNCI., 2007 - books.google.com
Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) is a recombinant
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …
monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat …